Promising combo for tough leukemia falls short – trial halted
NCT ID NCT04874194
First seen Nov 03, 2025 · Last updated Jun 05, 2026 · Updated 24 times
Summary
This study tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or treatment-resistant acute myeloid leukemia or myelodysplastic syndrome that had a specific genetic change called RUNX1. The goal was to find the best dose and see if the combo could help control the disease by killing cancer cells and blocking a protein they need to survive. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.